The serum levels of IL-6 and IL-8 in NAFLD rats were significantly decreased in the middle- and high-dose AS-IV–treated groups (p < 0.05) (Figure 6). Here, CXCL8 is linked to metabolic dysfunction-associated steatotic liver disease.